Jeffery L. Cummings, MD, ScD

Jeffery L. Cummings, MD, ScD is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Camille and Larry Ruvo Chair for Brain Health of the Neurological Institute of Cleveland Clinic. The Lou Ruvo Center for Brain Health is a clinical care, translational research, and clinical trials enterprise specializing in care of patients with neurocognitive deficits and development of new therapies for neurodegenerative disorders.

Dr. Cummings is an experienced clinical trialist with expertise in clinical trial design and analysis, global trial implementation, and trial outcome measures. He is the author of the Neuropsychiatric Inventory (NPI), the most commonly used tool for clinical trials characterizing behavioral disturbances in dementia syndromes.

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited over 30 books and published over 600 peer-reviewed papers.

Jill Rasmussen, MBChB, FRCGP, FFPM

Jill Rasmussen MBChB, FRCGP, FFPM is a clinician with special interest in psychiatry and neurology. Following an initial period of nine years in the NHS she worked in the pharmaceutical industry in Europe, the US and UK for ten years where she held senior positions in a number of companies with responsibility for the development of new drugs for psychiatry and neurology. Dr Rasmussen also spent two years with the Medicines Control Agency (now the MHRA). Since 1994, she has combined part-time clinical practice with her own independent research consultancy (www.psi-napse.com). In her consultancy she specializes in advising on development and medico-marketing strategy for drugs in CNS indications (includes NICE HTAs), is an advisor to venture capital groups and is a member of the Wellcome Trust Pathfinder Awards Committee. In the NHS, Dr Rasmussen served as GP with Special Interest in Mental Health, Dementia and Learning Disability. Dr Rasmussen also has experience as a commissioner, and has national roles as RCGP Clinical Lead for Dementia, representative for dementia for NHS England Dementia Team South Region, Chair of the Lewy Body Society Specialist Advisory Group and Primary Care Representative on the Royal College Psych Old Age Faculty.

Scott Reines, MD, PhD

Scott Reines MD, PhD has led the clinical development of important new drugs in five different therapeutic areas. As Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson, he oversaw the development and approval of INVEGA and INVEGA SUSTENNA for schizophrenia, NUCYNTA for moderate to severe pain, REMINYL ER for Alzheimer’s disease, RISPERDAL CONSTA for schizophrenia and bipolar disorder, RISPERDAL for treatment of the autism, and TOPAMAX for prevention of migraine and seizures. At J&J he was responsible for all CNS and Pain products, as well as for Clinical Pharmacology and Pharmacogenomics, and was a member of the J&J Pharmaceutical R&D Board of Directors. Previously, Dr Reines was Vice President, Clinical Research at Merck, with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. There he led the development of EMEND for prevention of chemotherapy-induced nausea and vomiting, MAXALT for treatment of migraine headache, SINEMET-CR for Parkinson’s disease, and TRUSOPT, COSOPT, and TIMOPTIC-XE for prevention of glaucoma. Currently Dr. Reines consults for biotech, pharmaceutical, and venture firms, is a member of two Scientific Advisory Boards, and Chair of a Data Safety Monitoring Board. He is also a member of two non-profit boards, serving as Vice Chair of the Board of Directors of KidsPeace, a large children’s psychiatric healthcare provider, and as a member of the Board of Directors of Heritage Conservancy, directed toward land preservation. Dr Reines also served for two years as co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and spent five years on the National Drug Abuse Advisory Council. He holds a bachelor’s degree in chemistry from Cornell University, a PhD in chemistry/molecular biology from Columbia University, and an MD from Albert Einstein College of Medicine. He is Board Certified in Psychiatry and Neurology.

Pierre Tariot, MD

Pierre Tariot MD is Director, Banner Alzheimer’s Institute, Research Professor of Psychiatry at University of Arizona College of Medicine. Dr. Tariot is a Phi Beta Kappa graduate of Amherst College who attended the University of Rochester School of Medicine. He completed residencies in Internal Medicine and Psychiatry at the University of Wisconsin in Madison, Wisconsin, and is Board Certified in both specialties, with added qualifications in geriatrics. He served as a Fellow at the Intramural Research Program of the National Institute of Mental Health. In 1986, he joined the faculty of the University of Rochester Medical Center, achieving the rank of Professor of Psychiatry, Medicine, Neurology, and Aging and Developmental Biology; while there, he served as Director of the Memory Disorders Clinic, Director of Psychiatry at Monroe Community Hospital, and Director of the University of Rochester component of the NIA-funded Alzheimer’s Disease Cooperative Study. Since 2006, he has been at the Banner Alzheimer’s Institute, where he serves as Director. Dr. Tariot has investigated, and lectured extensively on, multiple aspects of diagnosis, therapy and prevention of Alzheimer’s disease, and has published over 350 papers on these topics. He has served as author for several studies that have led to FDA approval of treatments for Alzheimer’s disease. He has led efforts to refine our ability to measure behavioral changes in dementia and contributed to large multicenter trials of a range of treatments for these neuropsychiatric features. He has participated in efforts to identify novel therapies for Alzheimer’s as well as to develop novel clinical trials methods for studying them. Together with his colleague and friend, Eric Reiman, he serves as co-director of the Alzheimer’s Prevention Initiative, an NIH-funded international program to study experimental therapies that may delay or even prevent the symptoms of Alzheimer’s in people at high imminent risk. Dr. Tariot leads the Banner "Dementia Care Initiative," a program designed to demonstrate the clinical and cost-effectiveness of standardized care for persons with dementia in a large health care system. He is a Research Professor of Psychiatry at the University of Arizona College of Medicine and a member of the American College of Neuropsychopharmacology. He has earned several awards for his research, including the American Geriatrics Society New Investigator Award for Neuroscience, an NIMH Geriatric Mental Health Academic Award, the 2005 UCLA Turken Award, and he was named the 2012 Geriatrician of the Year by the Arizona Geriatrics Society. Dr. Tariot’s research affiliations include the National Institute of Mental Health, the New York State Department of Health, Arizona Department of Health, the National Institute on Aging, the Institute for Mental Health Research, and the Alzheimer’s Association.